How the NHS Changed Its Mind on an Ovarian Cancer Drug

The NHS approved a new ovarian cancer drug called Elahere on June 4, reversing an earlier rejection. The health service appears to have negotiated a better price with the drug maker, AbbVie, though the actual deal remains secret. This shift hints at a larger trend: health systems are willing to bypass traditional cost checks for rare cancers, raising questions about how drug access decisions really work.